RT Journal Article SR Electronic T1 ▼Rivastigmine for Alzheimer's disease JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 15 OP 16 DO 10.1136/dtb.2000.38215 VO 38 IS 2 YR 2000 UL http://dtb.bmj.com/content/38/2/15.abstract AB Relevant BNF section: 4.11▼Rivastigmine (Exelon - Novartis) is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows ▼donepezil (Aricept - Eisai; Pfizer). Previously, we have been "unconvinced of the value of donepezil in routine clinical practice".1,2 Rivastigmine has been promoted with the slogan "Beyond cognition: improving functional ability". Does rivastigmine offer useful benefits in Alzheimer's disease?